Eylea is an Effective Treatment for Macular Degeneration and Costs Less than Current Similar Medicine EYLEA™ (aflibercept) was approved in December 2011 for the treatment of neovascular (wet) macular degeneration. Eylea (by Regeneron) works much like Lucentis and Avastin in its treatment of macular degeneration except that it is used less frequently and costs less. The recommended dose for EYLEA is 2 mg (0.05 mL) administered by injection into the vitreous of the eye every 4 weeks (monthly) for the first 3 months followed by 2 mg (0.05 mL) via injection once every 8 weeks (2 months).
DISCLAIMER: The information on this website is for educational purposes only. The information on this website is not meant to diagnose or treat any disease(s). Only a licensed doctor can diagnose or treat disease. No information on this website has been evaluated by the U.S. Food and Drug Administration.